基质金属蛋白酶9在COMET治疗的慢性眼部Stevens-Johnson综合征中的预后意义
该前瞻性研究纳入45眼慢性眼部Stevens-Johnson综合征(SJS)接受培养口腔黏膜上皮移植(COMET)的患眼,用免疫组化和qPCR检测MMP2、MMP3、MMP9、MMP11及TIMP1表达,并随访1年行MMP9免疫测定。结果显示MMP9和MMP11在翼状胬肉上皮和基质层均有阳性表达,高MMP9基质表达与术前角膜角化、结膜充血和睑球粘连显著相关;高MMP9和高MMP3上皮表达是COMET术后BCVA预后不良的独立危险因素,多因素分析显示MMP9是最佳预后标志物(p=0.050)。
要点
- 高MMP9基质表达与术前角膜角化(p=0.011)、结膜充血(p=0.014)、睑球粘连(p=0.028)显著相关。
- 高MMP9上皮表达(p=0.022)和高MMP3上皮表达(p=0.048)是COMET术后BCVA预后不良的独立危险因素。
- 多因素分析显示MMP9是COMET术后BCVA的最佳预后标志物(p=0.050)。
核心结论
- 慢性SJS中MMPs与TIMP1存在差异表达,MMP9是COMET术后BCVA不良预后的预测因子。
研究设计与样本
- 前瞻性研究纳入45眼慢性SJS接受COMET进行视觉和解剖康复的患眼,记录术前术后临床参数。
- 采用免疫组化和定量实时PCR评估MMP2、MMP3、MMP9、MMP11及TIMP1表达,随访1年行Inflammadry MMP9检测。
- 使用Kaplan-Meier曲线和Cox比例风险模型分析蛋白表达与临床病理参数及COMET植片存活结局的相关性。
主要发现
- MMP9和MMP11在翼状胬肉上皮阳性率分别为48%和55%,在基质层分别为57%和33%。
- MMP2和MMP3仅在上皮阳性,阳性率分别为35%和51%。
- 高MMP9基质表达与术前角膜角化(p=0.011)、结膜充血(p=0.014)、睑球粘连(p=0.028)显著相关。
- 高MMP9上皮表达(p=0.022)和高MMP3上皮表达(p=0.048)是COMET术后BCVA预后不良的独立危险因素。
- 多因素分析显示MMP9是最佳预后标志物(p=0.050)。
关键数值与推荐
- 高MMP9基质表达与术前角膜角化相关(p=0.011)。
- 高MMP9基质表达与结膜充血相关(p=0.014)。
- 高MMP9基质表达与睑球粘连相关(p=0.028)。
- 高MMP9上皮表达是COMET术后BCVA预后不良的独立危险因素(p=0.022)。
- 高MMP3上皮表达是COMET术后BCVA预后不良的独立危险因素(p=0.048)。
临床怎么用
- COMET术前检测MMP9基质表达可能有助于识别术后BCVA预后不良的高风险慢性SJS患眼。
- 术后1年MMP9免疫测定阳性可作为研究慢性SJS持续眼表炎症的潜在工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Molecular pathogenesis underlying persistent ocular surface inflammation in chronic Stevens-Johnson syndrome (SJS) still remains largely unexplored. The present study investigates the expression of matrix metalloproteinase 2 (MMP2), MMP3, MMP9, MMP11 and TIMP1 (tissue inhibittor of matrix metalloproteinase 1) in pannus tissues of chronic ocular SJS undergoing cultivated oral mucosal epithelial transplantation (COMET) and their prognostic relevance. METHODS: In this prospective study, 45 eyes with chronic SJS underwent COMET for visual and anatomical rehabilitation. Preoperative and postoperative clinical parameters were documented. MMP2, MMP3, MMP9, MMP11 and TIMP1 expression were assessed using immunohistochemistry and quantitative real time PCR. Inflammadry MMP9 assay was performed at 1-year follow-up. Kaplan-Meier curves and Cox proportional hazard models were used to correlate protein expression with clinicopathological parameters and COMET graft survival outcomes. RESULTS: MMP9 and MMP11 positivity was seen in both pannus epithelia (48% and 55%, respectively) and in stromal layer (57% and 33%, respectively) while MMP2 and MMP3 showed only pannus epithelial positivity in 35% and 51% cases, respectively. High MMP9 stromal expression was significantly associated with preoperative corneal keratinisation (p=0.011), conjunctival hyperaemia (p=0.014), symblepharon (p=0.028). High MMP9 and MMP3 epithelial expression were found to be independent risk factors for poor best-corrected visual acuity (BCVA) outcomes post-COMET (p=0.022 and p=0.048). Multivariate analysis revealed MMP9 to be the best prognostic marker (p=0.050). CONCLUSION: Our findings suggest that differential expression of MMPs and TIMP1 is seen in SJS in chronic stage. Emergence of MMP9 as a poor prognostic predictor of BCVA post COMET and postoperative MMP9 immunoassay positivity could be a useful tool in further studies to understand the unresolved ocular surface inflammation seen in SJS.
引用
- Venugopal R, Sharma N, Sen S, et al. Prognostic significance of matrix metalloproteinase 9 in COMET operated chronic ocular Stevens-Johnson syndrome. Br J Ophthalmol. 2021. PMID: 34362775. doi:10.1136/bjophthalmol-2021-319302
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。